- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Lee Schwartzberg, MD, FACP: Lessons Learned From Supportive Care Biosimilars
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses what oncologists have learned from experience with supportive care that can be applied to adopting anticancer biosimilars.
Transcript
We've been using supportive care biosimilars for a couple of years now; the supportive care drugs tend to be slotted in a little different way in some practices. They're chosen at the practice level rather than at the regimen level, so that they're organized to go into different categories of regimens rather than individual regimens.
Of course, physicians pick the regimens with therapeutics, so a little different, they're a little different slant. But again, the comfort with using the supportive care regimens, the principles are the same. You have a drug, you've manufactured a drug that's highly similar, that's going to work the same, whether it's in supportive care or therapeutic. If you trust that, you can use it.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
